Northern Trust
DMAC icon

Northern Trust’s DiaMedica Therapeutics DMAC Stock Holding History

Northern Trust’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
338,526
+12,999
+4% +$103K ﹤0.01% 2900
2025
Q4 		$2.59M Sell
325,527
-14,051
-4% -$105K ﹤0.01% 2842
2025
Q3 		$2.33M Buy
339,578
+15,040
+5% +$81.6K ﹤0.01% 2944
2025
Q2 		$1.27M Buy
324,538
+147,258
+83% +$574K ﹤0.01% 3256
2025
Q1 		$672K Sell
177,280
-2,912
-2% -$16.6K ﹤0.01% 3450
2024
Q4 		$978K Buy
180,192
+59,902
+50% +$282K ﹤0.01% 3404
2024
Q3 		$504K Sell
120,290
-99
-0.1% -$365 ﹤0.01% 3579
2024
Q2 		$355K Sell
120,389
-7,430
-6% -$20.4K ﹤0.01% 3631
2024
Q1 		$354K Sell
127,819
-5,814
-4% -$16.9K ﹤0.01% 3683
2023
Q4 		$380K Buy
133,633
+43,933
+49% +$109K ﹤0.01% 3640
2023
Q3 		$231K Buy
89,700
+7,540
+9% +$24.2K ﹤0.01% 3751
2023
Q2 		$355K Sell
82,160
-8,665
-10% -$21K ﹤0.01% 3627
2023
Q1 		$139K Sell
90,825
-2,243
-2% -$3.56K ﹤0.01% 3987
2022
Q4 		$147K Buy
93,068
+2,814
+3% +$3.79K ﹤0.01% 3981
2022
Q3 		$112K Sell
90,254
-11,450
-11% -$17.9K ﹤0.01% 4077
2022
Q2 		$206K Buy
101,704
+1,762
+2% +$4.11K ﹤0.01% 3910
2022
Q1 		$250K Sell
99,942
-1,341
-1% -$3.8K ﹤0.01% 4044
2021
Q4 		$378K Buy
101,283
+15,713
+18% +$61.7K ﹤0.01% 3910
2021
Q3 		$343K Buy
85,570
+375
+0.4% +$1.44K ﹤0.01% 3917
2021
Q2 		$379K Buy
85,195
+169
+0.2% +$1.39K ﹤0.01% 3836
2021
Q1 		$778K Sell
85,026
-35,963
-30% -$336K ﹤0.01% 3679
2020
Q4 		$1.23M Buy
120,989
+4,222
+4% +$23.1K ﹤0.01% 3432
2020
Q3 		$495K Buy
116,767
+20,896
+22% +$111K ﹤0.01% 3609
2020
Q2 		$664K Buy
95,871
+83,406
+669% +$372K ﹤0.01% 3478
2020
Q1 		$35K Buy
+12,465
New +$51.5K ﹤0.01% 4007

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust's DMAC Position: Q1 2026 in Review

Northern Trust increased its DiaMedica Therapeutics (DMAC) stake by 4% in Q1 2026, buying an estimated $103K and bringing the position to 338,526 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2900.

Northern Trust first reported a position in DMAC in Q1 2020 and has held it in 25 quarters since. The position peaked at $2.59M in Q4 2025. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Northern Trust held 338,526 shares of DiaMedica Therapeutics worth $2.29M as of Q1 2026.
  • Northern Trust bought 12,999 DiaMedica Therapeutics shares in Q1 2026, an estimated $103K.
  • DiaMedica Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2900 holding.
  • Northern Trust first reported a position in DiaMedica Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Northern Trust's DiaMedica Therapeutics position peaked at $2.59M in Q4 2025.
  • 99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.